- Home
- TIL vs TDAC Comparison
TIL vs TDAC Comparison
Compare TIL & TDAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- TDAC
- Stock Information
- Founded
- TIL 2018
- TDAC 2022
- Country
- TIL United States
- TDAC United States
- Employees
- TIL N/A
- TDAC N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- TDAC
- Sector
- TIL Health Care
- TDAC
- Exchange
- TIL Nasdaq
- TDAC NYSE
- Market Cap
- TIL 230.1M
- TDAC 221.0M
- IPO Year
- TIL 2021
- TDAC 2024
- Fundamental
- Price
- TIL $23.14
- TDAC $10.27
- Analyst Decision
- TIL Buy
- TDAC
- Analyst Count
- TIL 5
- TDAC 0
- Target Price
- TIL $119.00
- TDAC N/A
- AVG Volume (30 Days)
- TIL 387.8K
- TDAC 18.2K
- Earning Date
- TIL 08-12-2025
- TDAC 01-01-0001
- Dividend Yield
- TIL N/A
- TDAC N/A
- EPS Growth
- TIL N/A
- TDAC N/A
- EPS
- TIL N/A
- TDAC 0.16
- Revenue
- TIL N/A
- TDAC N/A
- Revenue This Year
- TIL N/A
- TDAC N/A
- Revenue Next Year
- TIL N/A
- TDAC N/A
- P/E Ratio
- TIL N/A
- TDAC $160.48
- Revenue Growth
- TIL N/A
- TDAC N/A
- 52 Week Low
- TIL $9.62
- TDAC $10.00
- 52 Week High
- TIL $92.00
- TDAC $10.30
- Technical
- Relative Strength Index (RSI)
- TIL 43.15
- TDAC N/A
- Support Level
- TIL $21.29
- TDAC N/A
- Resistance Level
- TIL $31.67
- TDAC N/A
- Average True Range (ATR)
- TIL 3.95
- TDAC 0.00
- MACD
- TIL -1.71
- TDAC 0.00
- Stochastic Oscillator
- TIL 8.60
- TDAC 0.00
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About TDAC TRANSLATIONAL DEVELOPMENT ACQUISITI
Translational Development Acquisition Corp is a newly organized blank check company.